# KRAS G12C

Source: https://onco.cc/biomarkers/kras-g12c/  
OnCo record `kras-g12c` (Biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

KRAS G12C swaps glycine 12 for cysteine and was the first KRAS mutation a drug could grip. Sotorasib and adagrasib are approved for it in lung cancer, and with an EGFR antibody in bowel cancer.

## Summary

The c.34G>T (G12C) substitution is found in about 13 percent of lung adenocarcinomas and 3 to 4 percent of colorectal cancers. Sotorasib and adagrasib are labelled as single agents for KRAS G12C-mutated locally advanced or metastatic NSCLC after at least one prior systemic therapy, and in colorectal cancer sotorasib with panitumumab and adagrasib with cetuximab after prior chemotherapy, each 'as determined by an FDA-approved test'. The therascreen KRAS RGQ PCR Kit, Guardant360 CDx, Agilent Resolution ctDx FIRST and FoundationOne CDx carry the claims. G12C is the only KRAS mutation with an approved drug; the other codon 12 and 13 mutations are used as negative selectors for EGFR antibodies in colorectal cancer.

## Fields

- Kind: Biomarker
- Last checked: 2026-09-23
- Also known as: KRAS G12C; G12C; KRAS p.G12C; KRAS c.34G>T; KRAS G12C-mutated
- Tags: biomarker; kras

## Sources

- LUMAKRAS prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c80a362c-7ac3-4894-a076-0691e68ef8c1
- KRAZATI prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b8bf078-34c2-4f45-9012-38a8ac082b01

## Connected records

- biomarkers: [BRAF V600E (and V600K)](https://onco.cc/biomarkers/braf-v600e/), [KRAS G12D (and other non-G12C KRAS mutations)](https://onco.cc/biomarkers/kras-g12d/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Adagrasib](https://onco.cc/drugs/adagrasib/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [Divarasib](https://onco.cc/drugs/divarasib/), [Guardant360 CDx](https://onco.cc/drugs/guardant360-cdx/), [Olomorasib](https://onco.cc/drugs/olomorasib/), [Panitumumab](https://onco.cc/drugs/panitumumab/), [Sotorasib](https://onco.cc/drugs/sotorasib/), [therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)](https://onco.cc/drugs/therascreen-cdx/)
- terms: [KRAS mutation subtypes (G12C, G12D, G12V)](https://onco.cc/terms/kras-mutation-subtypes/), [Next-generation sequencing (NGS)](https://onco.cc/terms/ngs/)
- targets: [KRAS](https://onco.cc/targets/kras/)

---
JSON: https://onco.cc/api/v1/entities/kras-g12c.json